Consensus statement on the treatment of allergic rhinitis

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 55, Issue 2, 2000, Pages 116-134

  Van Cauwenberge, P ^a   Bachert, C ^a   Passalacqua, G ^a   Bousquet, J ^a   Canonica, G W ^a   Durham, S R ^a   Fokkens, W J ^a   Howarth, P H ^a   Lund, V ^a   Malling, H J ^a   Mygind, N ^a   Passali, D ^a   Scadding, G K ^a   Wang, D Y ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIVASTINE; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ASTEMIZOLE; AZELASTINE; BECLOMETASONE DIPROPIONATE; CETIRIZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DECONGESTIVE AGENT; EBASTINE; ERYTHROMYCIN; FEXOFENADINE; FLUTICASONE PROPIONATE; IPRATROPIUM BROMIDE; KETOCONAZOLE; LEVOCABASTINE; LORATADINE; MIZOLASTINE; MOMETASONE FUROATE; NEDOCROMIL SODIUM; OXYMETAZOLINE; PHENYLEPHRINE; TERFENADINE; UNINDEXED DRUG; XYLOMETAZOLINE;

ADULT; ALLERGIC RHINITIS; ALLERGY; CHILD; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FOOD DRUG INTERACTION; HEART ARRHYTHMIA; HUMAN; IMMUNOTHERAPY; INSOMNIA; PRACTICE GUIDELINE; PRICK TEST; PRIORITY JOURNAL; REVIEW; RHINITIS; TASTE DISORDER;

ADULT; CHILD; CHOLINERGIC ANTAGONISTS; DESENSITIZATION, IMMUNOLOGIC; GLUCOCORTICOIDS; HISTAMINE H1 ANTAGONISTS; HUMANS; NASAL DECONGESTANTS; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL;

EID: 0033963977     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1398-9995.2000.00526.x     Document Type: Review

References (185)

1. 1. WÜTHRICH B, SCHINDLER C, LEUENBERGER P, ACKERMANN-LIEBRICH U. Prevalence of atopy and pollinosis in the adult population of Switzerland (SAPALDIA study). Swiss Study on Air Pollution and Lung Diseases in Adults. Int Arch Allergy Immunol 1995;106:149-156.
2. 2. MYGIND N, DAHL R. Epidemiology of allergic rhinitis. Pediatr Allergy Immunol 1996;7 Suppl 9:57-62.
3. 3. SIBBALD B. Epidemiology of allergic rhinitis. In: BURR ML, editor. Epidemiology of clinical allergy. Monographs in allergy. Basel: Karger, 1993:61-69.
4. 4. International Rhinitis Management Working Group. International Consensus Report on the Diagnosis and Management of Rhinitis. Allergy 1994;49 Suppl 9:5-34.
5. 5. SIBBALD B, RINK E. Epidemiology of seasonal and perennial rhinitis: clinical presentation and medical history. Thorax 1991;46:859-901.
6. 6. ÅBERG N, SUNDELL J, ERIKSSON B, HESSELMAR B, ÅBERG B. Prevalence of allergic diseases in schoolchildren in relation to family history, upper respiratory tract infections, and residential characteristics. Allergy 1996;51:232-237.
7. 7. SIBBALD B, RINK E, D'SOUZA M. Is the prevalence of atopy increasing? Br J Gen Pract 1990;40:338-340.
8. 8. BOUSQUET J, BULLINGER M, FAYOL C, MARQUIS P, VALENTIN B, BURTIN B. Assessment of the quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J Allergy Clin Immunol 1994;94:182-188.
9. 9. JUNIPER EF, GUYATT GH, DOLVICH J. Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol 1994;93:413-423.
10. 10. SPAETH J, KLIMEK L, MOSGES R. Sedation by allergic rhinitis is caused by the condition and not by the antihistamine treatment. Allergy 1996;51:903-906.
11. 11. VUURMAN EF, VAN VEGGEL LM, UITERWIJK MM, LEUTNER D, O'HANLON JF. Seasonal allergic rhinitis and antihistamine's effects on children's learning. Ann Allergy 1993;71:121-126.
12. 12. SIMONS FE. Learning impairment and allergic rhinitis. Allergy Asthma Proc 1996;17:185-189.
13. 13. European Allergy White Paper, UCB Institute of Allergy, 1997.
14. 14. SPECTOR SL. Overview of comorbid associations of allergic rhinitis. J Allergy Clin Immunol 1997;99:S773-780.
15. 15. NACLERIO RM. Allergic rhinitis. N Engl J Med 1991;325:860-869.
16. 16. BOUSQUET J, VIGNOLA AM, CAMPBELL AM, MICHEL FB. Pathophysiology of allergic rhinitis. Int Arch Allergy Immunol 1996;110:207-218.
17. 17. BENTLEY AM, JACOBSON MR, CUMBERWORTH V, et al. Immunohistology of the nasal mucosa in seasonal allergic rhinitis: increases in activated eosinophils and epithelial mast cells. J Allergy Clin Immunol 1992;89:877-883.
18. 18. DURHAM SR. Mechanisms of mucosal inflammation in the nose and lungs. Clin Exp Allergy 1998;28 Suppl 2:11-16.
19. 19. CANONICA GW, CIPRANDI G, BUSCAGLIA S, PESCE G, BAGNASCO M. Adhesion molecules of allergic inflammation: recent insights into their functional roles. Allergy 1994;49:135-141.
20. 20. MONTEFORT S, ROCHE WR, HOWARTH P, et al. Intercellular adhesion molecule-1 (ICAM-1) and endothelial leukocyte adhesion molecule-1 (ELAM-1) expression in the bronchial mucosa of normal and asthmatic subjects. Eur Respir J 1992;5:815-823.
21. 21. DURHAM SR, YING S, VARNEY VA, et al. Cytokine messenger RNA expression for IL-3, IL-4, IL-5 and granulocyte/ macrophage-colony-stimulating-factor in the nasal mucosa after local allergen provocation: relationship to tissue eosinophilia. J Immunol 1992;148:2390-2394.
22. 22. BRADDING P, FEATHER IH, WILSON S, et al. Immunolocalization of cytokines in the nasal mucosa of normal and perennial allergic rhinitis subjects. The mast cell as a source of IL-4, IL-5 and IL-6 in human allergic mucosal inflammation. J Immunol 1993;151:3853-3865.
23. 23. WILSON SJ, LAU L, HOWARTH PH. Inflammatory mediators in naturally occurring rhinitis. Clin Exp Allergy 1998;28:220-227.
24. 24. PIPKORN U, KARLSSON G, ENERBÅCK L. Nasal mucosal response to repeated challenges with pollen allergen. Am Rev Respir Dis 1989;140:729-736.
25. 25. HOWARTH PH. Mucosal inflammation and allergic rhinitis. In: Naclerio RM, Durham SR, Mygind N, editors. Rhinitis mechanisms and management. New York: Dekker, 1999:109-134.
26. 26. DEL PRETE GF, DE CARLI M, D'ELIOS MM, et al. Allergen exposure induces the activation of allergen-specific Th2 cells in the airway mucosa of patients with allergic respiratory disorders. Eur J Immunol 1993;23:1445-1449.
27. 27. MONTEFORT S, HOLGATE ST, HOWARTH PH. Leucocyte-endothelial adhesion molecules and their role in bronchial asthma and allergic rhinitis. Eur Respir J 1993;6:1044-1054.
28. 28. KUNA P, LAZAROVICH M, KAPLAN AP. Chemokines in seasonal allergic rhinitis. J Allergy Clin Immunol 1996;97:104-112.
29. 29. BACHERT C, VAN KEMPEN M, VAN CAUWENBERGE P. Regulation of proinflammatory cytokines in seasonal allergic rhinitis. Int Arch Allergy Immunol 1999;118:375-379.
30. 30. CIPRANDI G, BUSCAGLIA S, PESCE G, et al. Minimal persistent inflammation is present at mucosal level in patients with asymptomatic rhinitis and mite allergy. J Allergy Clin Immunol 1995;96:971-979.
31. 31. PLATTS-MILLS TA, CHAPMAN MD. Dust mites: immunology, allergic disease, and environmental control. J Allergy Clin Immunol 1987;80:755-775.
32. 32. KORSGAARD J. Mite asthma and residency. A case control study of the impact of exposure to house dust mites. Am Rev Respir Dis 1983;128:231-235.
33. 33. SEARS MR, HERBISON GP, HOLDAWAY MD, HEWITT CJ, FLANNERY EM, SILVA PA. The relative risk of sensitivity to grass pollen, house dust mite and cat dander in the development of childhood asthma. Clin Exp Allergy 1989;19:419-424.
34. 34. Global strategy for asthma management and prevention. WHO/ NHLBI workshop report, 1995. Publication no. 95-3659.
35. 35. BONER AL, NIERO E, ANTOLINI I, et al. Pulmonary function and bronchial hyperreactivity in asthmatic children with house dust mite allergy during prolonged stay in Italian Alps. Ann Allergy 1985;55:42-45.
36. 36. WOODFOLK JA, HAYDEN ML, MILLER JD, MILLER A. Chemical treatment of carpets to reduce allergens. A detailed study of tannic acid on indoor allergens. J Allergy Clin Immunol 1994;94:19-23.
37. 37. MITCHELL EB, WILKINS S, DEIGHTON JM. Reduction of house dust mite allergens in the home: use of the acaricide pirimiphos methyl. Clin Exp Allergy 1985;15:235-240.
38. 38. HAYDEN ML, ROSE G, DIDUCH KC. Benzyl benzoate moist powder investigation of acaricide activity in culture and reduction of allergen in carpets. J Allergy Clin Immunol 1992;89:536-540.
39. 39. ENHERT B, LAU-SCHADENDORF S, WEBER A, et al. Reducing domestic exposure to dust mite allergen reduces bronchial hyperreactivity in sensitive children with asthma. J Allergy Clin Immunol 1992;90:135-138.
40. 40. VAN DER HEIDE S, KAUFFMAN HF, DUBOIS AE, DE MONCHY JG. Allergen-avoidance measures in homes of house-dust-mite-allergic asthmatic patients: effects of acaricides and mattress encasings. Allergy 1997;52:921-927.
41. 41. MILLER D, MILLER A. Effects of washing and drying on mite in blankets. J Allergy Clin Immunol 1993;91:251-254.
42. 42. GØTZSCHE PC, HAMMARQUIST C, BURR M. House dust mite control measures in the management of asthma: meta-analysis. BMJ 1998;317:1105.
43. 43. DE BLAY F, CHAPMAN MD, PLATTS-MILLS TAE. Airborne cat allergens (Fel d 1). Environmental control with the cat in situ. Am Rev Respir Dis 1991;143:1334-1339.
44. 44. KLUCKA CV, OWNBY DR, GREEN J, ZORATTI E. Cat shedding of Fel d I is not reduced by washings, Allerpet-C spray or acepromazine. J Allergy Clin Immunol 1995;95:1164-1171.
45. 45. WANG DY, CLEMENT P, SMITZ J, DE WAELE M, DERDE MP. Correlations between complaints, inflammatory cells and mediators after nasal allergen challenge and during natural allergen exposure. Int Arch Allergy Immunol 1995;106:278-285.
46. 1 antihistamines, terfenadine and astemizole, for hay fever. Thorax 1984;39:668-672.
47. 47. NACLERIO RM, TOGIAS AG. The nasal allergic reaction: observations on the role of histamine. Clin Exp Allergy 1991;21 Suppl 2:13-19.
48. 2 antagonists on nasal symptoms and mediator release in atopic patients after nasal allergen challenge during the pollen season. Acta Otolaryngol (Stockh) 1996;116:91-96.
49. 49. BROOKS CD, KARL KJ, FRANCOM SF. Profile of ragweed hay fever symptom control with terfenadine started before or after symptoms are established. Clin Exp Allergy 1990;20:21-26.
50. 50. JANSSENS MM. Astemizole. A nonsedating antihistamine with fast and sustained activity. Clin Rev Allergy 1993;11:35-63.
51. 51. CAMPOLI-RICHARDS DM, DUCKLEY MM, FITTON A. Cetirizine. A review of its pharmacological properties and clinical potential in allergic rhinitis, pollen-induced asthma, and chronic urticaria. Drugs 1990;4:762-781.
52. 52. ROBERTS DJ. A preclinical overview of ebastine. Drugs 1996;52 Suppl 1:8-14.
53. 53. MARKHAM A, WAGSTAFF AJ. Fexofenadine. Drugs 1998;55:269-274.
54. 54. HARIA M, FITTON A, PETERS DH. Loratadine. A reappraisal of its pharmacological properties and therapeutic use in allergic disorders. Drugs 1994;48:617-637.
55. 55. LEYNADIER F, BOUSQUET J, MURRIETA M, ATTALI P. Efficacy and safety of mizolastine in seasonal allergic rhinitis. The Rhinase Study Group. Ann Allergy Asthma Immunol 1996;76:163-168.
56. 56. SORKIN EM, HEEL RC. Terfenadine. Review of its pharmacodynamic properties and clinical efficacy. Drugs 1985;29:34-56.
57. 1-receptor antagonist drugs. J Allergy Clin Immunol 1996;98:S307-318.
58. 58. CIPRANDI G, PASSALACQUA G, AZZARONE B, BAGNASCO M, CANONICA GW. Molecular events in allergic inflammation: expression of adhesion molecules and their modulation. In: MARONE G, editor. Asthma and allergic diseases. San Diego, CA: Academic Press, 1998:309-320.
59. 59. SHIN MH, BAROODY F, PROUD D, et al. The effect of azelastine on the early allergic response. Clin Exp Allergy 1992;22:289-295.
60. 60. TABORDA-BARATA L, JACOBSON M, WALKER S, et al. Effect of cetirizine and prednisolone on cellular infiltration and cytokine mRNA expression during allergen-induced late cutaneous responses. Clin Exp Allergy 1996;26:68-78.
61. 61. BRONSKY EA, DOCKHORN RJ, MELTZER EO, et al. Fluticasone propionate aqueous nasal spray compared with terfenadine tablets in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1996;97:915-921.
62. 62. ROQUET A, RAND J, HALLDEN G, et al. Effect of loratadine on anti-IgE-induced inflammation, histamine release and leucocyte recruitment in skin of atopics. Allergy 1995;50:414-420.
63. 1-receptor antagonists. Clin Pharmacokinet 1991;21:372-393.
64. 1 receptor antagonists. Allergy 1996;51:666-675.
65. 65. RANKIN AC. Non-sedating antihistamines and cardiac arrhythmia. Lancet 1997;350:1115-1116.
66. 66. HINDMARCH I. Psychometric aspects of antihistamines. Allergy 1995;50:48-54.
67. 67. MYGIND N, DAHL R, PEDERSEN S, THESTRUP-PEDERSEN K, editors. Essential allergy. 2nd edn. London: Blackwell Science, 1996:195-252.
68. 68. FALLIERS CJ, BRANDON ML, BUCHMAN E, et al. Double-blind comparison of cetirizine and placebo in the treatment of seasonal rhinitis. Ann Allergy 1991;66:257-262.
69. 69. CHERVINSKY P, GEORGITIS J, BANOV C, BOGGS P, VAN DE SOUWE R, GREENSTEIN S. Once daily loratadine versus astemizole once daily. Ann Allergy 1994;73:109-113.
70. 70. BRONSKY E, BOGGS P, FINDLAY S, et al. Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal rhinitis. J Allergy Clin Immunol 1995;96:139-147.
71. 71. BERTRAND B, JAMART J, MARCHAL JL, ARENDT C. Cetirizine and pseudoephedrine retard alone and in combination in the treatment of perennial allergic rhinitis: a double-blind multicentre study. Rhinology 1996;34:91-96.
72. 72. DAVIES RJ, LUND VJ, HARTEN-ASH VJ. The effect of intranasal azelastine and beclomethasone on the symptoms and signs of nasal allergy in patients with perennial allergic rhinitis. Rhinology 1993;31:159-164.
73. 73. RATNER PH, FINDLAY SR, HAMPEL F JR, VAN BAVEL J, WIDLITZ MD, FREITAG JJ. A double-blind, controlled trial to assess the safety and efficacy of azelastine nasal spray in seasonal allergic rhinitis. J Allergy Clin Immunol 1994;94:818-825.
74. 74. MCTAVISH DB, SORKIN EM. Azelastine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutical potential. Drugs 1989;38:778-800.
75. 75. DECHANT KL, GOA KL. Levocabastine. A review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis. Drugs 1991;41:202-224.
76. 76. DAVIES BH, MULLINS J. Topical levocabastine is more effective than sodium cromoglycate for the prophylaxis and treatment of seasonal allergic conjunctivitis. Allergy 1993;48:519-524.
77. 77. AZEVEDO M, CASTEL-BRANCO MG, OLIVEIRA JF, RAMOS E, DELGADO L, ALMEIDA J. Double-blind comparison of levocabastine eye drops with sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis. Clin Exp Allergy 1991;21:689-694.
78. 78. DAVIES RJ, BAGNALL AC, MCCABE RN, CALDERON MA, WANG JH. Antihistamines: topical versus oral administration. Clin Exp Allergy 1996;26 Suppl 3:11-17.
79. 79. DROUIN MA, YANG WH, HORAK F. Faster onset of action with topical levocabastine than with oral cetirizine. Mediators Inflamm 1995;4:S5-S10.
80. 80. ROMBAUT N, BHATTI JZ, CURRAN S, HINDMARCH I. Effects of topical administration of levocabastine on psychomotor and cognitive functions. Ann Allergy 1991;67:75-79.
81. 81. WANG D, CLEMENT P, SMITZ J, DE WAELE M. The activity of recent anti-allergic drugs in the treatment of seasonal allergic rhinitis. Acta Otorhinolaryngol Belg 1996;50:25-32.
82. 82. MYGIND N. Local effect of intranasal beclomethasone dipropionate aerosol in hay fever. BMJ 1973;4:464-466.
83. 83. FOKKENS WJ, GODTHELP T, HOLM AF, BLOM H, KLEIN-JAN A. Allergic rhinitis and inflammation: the effect of nasal corticosteroid therapy. Allergy 1997;52 Suppl 36:29-32.
84. 84. JULIUSSON S, HOLMBERG K, KARLSSON G, ENERBÄCK L, PIPKORN U. Mast cells and mediators in the nasal mucosa after allergen challenge. Effects of four weeks' treatment with topical glucocorticoids. Clin Exp Allergy 1993;23:591-599.
85. 85. RAK S, JACOBSON MR, SUDDERICK RM, et al. Influence of prolonged treatment with topical corticosteroid (fluticasone propionate) on early and late phase nasal responses and cellular infiltration in the nasal mucosa after allergen challenge. Clin Exp Allergy 1994;24:930-939.
86. 86. DAVIES RJ, NELSON HS. Once-daily mometasone furoate nasal spray: efficacy and safety of a new intranasal glucocorticoid for allergic rhinitis. Clin Ther 1997;1:27-38.
87. 87. MELTZER EO, ORGEL HA, BRONSKY EA, et al. A dose-ranging study of fluticasone propionate aqueous nasal spray for seasonal allergic rhinitis assessed by symptoms, rhinomanometry and nasal cytology. J Allergy Clin Immunol 1990;86:221-230.
88. 88. PIPKORN U, RUNDKRANTZ H, LINDQVIST N. Budesonide - a new nasal steroid. Rhinology 1980;18:171-175.
89. 89. BONER A, SETTE L, MARTINATI L, SHARMA R, RICHARDS D. The efficacy and tolerability of fluticasone propionate aqueous nasal spray in children with seasonal allergic rhinitis. Allergy 1995;50:498-505.
90. 90. DOLOVICH J, WONG A, CHODIRKER W. Multicenter trial of fluticasone propionate aqueous nasal spray in ragweed allergic rhinitis. Ann Allergy 1994;73:147-153.
91. 91. SIMPSON RJ. Budesonide and terfenadine, separately and in combination, in the treatment of hay fever. Ann Allergy 1994;73:497-502.
92. 92. GRAFT D, AARONSON D, CHERVINSKY P, et al. A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray. J Allergy Clin Immunol 1996;98:724-731.
93. 93. DROUIN M, YANG W, BERTRAND B, et al. Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients. Ann Allergy Asthma Immunol 1996;77:153-160.
94. 94. KOEPKE JW, BEAUCHER WN, KOBAYASHI RH, et al. Long term safety and efficacy of triamcinolone acetonide aqueous nasal spray for the treatment of perennial allergic rhinitis. Allergy Asthma Proc 1997;18:33-37.
95. 95. SCADDING GK, LUND VJ, JACQUES LA, RICHARDS DH. A placebo-controlled study of fluticasone propionate aqueous nasal spray and beclomethasone dipropionate in perennial rhinitis: efficacy in allergic and non-allergic perennial rhinitis. Clin Exp Allergy 1995;25:737-743.
96. 96. VAN AS A, BRONSKY EA, DOCKHORN RJ, et al. Once daily fluticasone propionate is as effective for perennial allergic rhinitis as twice daily beclomethasone dipropionate. J Allergy Clin Immunol 1993;91:1146-1154.
97. 97. ANDERSSON M, BERGLUND R, GREIFF L, et al. A comparison of budesonide nasal dry powder with fluticasone propionate aqueous nasal spray in patients with perennial allergic rhinitis. Rhinology 1995;33:18-21.
98. 98. EDELMANN A, VAN OS WAA. Safety of intranasal beclomethasone dipropionate - a review. Respir Care 1996;11:1025-1030.
99. 99. BROGDEN RN, MCTAVISH D. Budesonide. An updated review of its pharmacological properties and therapeutic efficacy in asthma and rhinitis. Drugs 1992;44:375-407.
100. 100. WISEMAN LR, BENFIELD P. Intranasal fluticasone propionate. A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis. Drugs 1997;53:885-907.
101. 101. JEAL W, FAULDS D. Triamcinolone acetonide. A review of its pharmacological properties and therapeutic efficacy in the management of allergic rhinitis. Drugs 1997;53:257-280.
102. 102. BUNNAG C, JAREONCHARSRI P, WONG EC. A double-blind comparison of nasal budesonide and oral astemizole for the treatment of perennial rhinitis. Allergy 1992;47:313-317.
103. 103. DARNELL R, PÉCOUD A, RICHARDS DH. A double-blind comparison of fluticasone propionate aqueous nasal spray, terfenadine tablets and placebo in the treatment of patients with seasonal allergic rhinitis to grass pollen. Clin Exp Allergy 1994;24:1144-1150.
104. 104. SVENSSON C, ANDERSSON M, GREIFF L, BLYCHERT LO, PERSSON CG. Effects of topical budesonide and levocabastine on nasal symptoms and plasma exudation responses in seasonal allergic rhinitis. Allergy 1998;53:367-374.
105. 105. BOUSQUET J, CHANAL I, ALQUIE MC, et al. Prevention of pollen rhinitis symptoms: comparison of fluticasone propionate aqueous nasal spray and disodium cromoglycate aqueous nasal spray. A multicenter, double-blind, double-dummy, parallel-group study. Allergy 1993;48:327-333.
106. 106. FISHER WG. Comparison of budesonide and disodium cromoglycate for the treatment of seasonal allergic rhinitis in children. Ann Allergy 1994;73:515-520.
107. 1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 1998;317:1624-1629.
108. 108. HOLM AF, FOKKENS WJ, GODTHELP T, MULDER PG, VROOM TM, RIJNTJES E. A 1-year placebo-controlled study of intranasal fluticasone propionate aqueous nasal spray in patients with perennial allergic rhinitis: a safety and biopsy study. Clin Otolaryngol 1998;23:69-73.
109. 109. SODERBERG-WARNER ML. Nasal septal perforation associated with topical corticosteroid therapy. J Pediatr 1984;105:840-841.
110. 110. PRENNER B. Hypothalamic pituitary adrenal axis suppression during inhaled or intranasal corticosteroid treatment. Adv Ther 1996;13:154-160.
111. 111. BRANNAN MD, HERRON JM, REIDENBERG P, AFFRIME MB. Lack of hypothalamic-pituitary-adrenal axis suppression with once-daily and twice-daily beclomethasone dipropionate aqueous nasal spray administered to patients with allergic rhinitis. Clin Ther 1995;17:637-647.
112. 112. HOWLAND WC, DOCKHORN R, GILLMAN S, et al. A comparison of effects of triamcinolone acetonide aqueous nasal spray, oral prednisone; and placebo on adrenocortical function in male patients with allergic rhinitis. J Allergy Clin Immunol 1996;98:32-38.
113. 113. NAYAK AS, ELLIS MH, GROSS GN, et al. The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis. J Allergy Clin Immunol 1998;101:157-162.
114. 114. HOWLAND WC. Fluticasone propionate: topical or systemic effects? Clin Exp Allergy 1996;26 Suppl 3:18-22.
115. 115. DAY J, ALEXANDER M, DROUIN M, et al. Budesonide aqueous nasal spray and pressurized metered dose inhaler in the treatment of adult patients with seasonal allergic rhinitis. Am J Rhinol 1997;11:77-83.
116. 116. RACHELEFSKY GS, CHERVINSKY P, MELTZER EO, MORRIS RM, SELTZER JM, SKONER DP, STORMS WW, WOOD RA. An evaluation of the effects of beclomethasone dipropionate on long-term growth in children. J Allergy Clin Immunol 1998;101:S236.
117. 117. BORUM P, GRONBORG H, MYGIND N. Seasonal allergic rhinitis and depot injection of corticosteroid. Evaluation of the efficacy of medication early and late in the season based on detailed symptom recording. Allergy 1987;42:26-32.
118. 118. LAURSEN LC, FAURSCHOU P, PALS H, SVENDSEN UG, WEEKE B. Intramuscular betamethasone dipropionate vs. oral prednisolone in hay fever patients. Allergy 1987;42:168-172.
119. 119. BROOKS CD, KARL KJ, FRANCOM SF. Oral methylprednisolone acetate (Medrol tablets) for seasonal rhinitis: examination of dose and symptom response. J Clin Pharmacol 1993;33:816-822.
120. 120. BRUIJNZEEL PL, WARRINGA RA, KOK PT, KREUKNIET J. Inhibition of neutrophil and eosinophil chemotaxis by nedocromil sodium and sodium cromoglycate. Br J Pharmacol 1990;99:798-802.
121. 121. LOZEWICZ S, GOMEZ E, CLAGUE J, GATLAND D, DAVIES RJ. Allergen induced changes in the nasal mucous membrane in seasonal allergic rhinitis: effect of nedocromil sodium. J Allergy Clin Immunol 1990;85:125-131.
122. 122. SCHATA M, JORDE W, RICHARZ-BARTHAUER U. Levocabastine nasal spray is better than sodium cromoglycate and placebo in the topical treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1991;87:873-878.
123. 123. ORGEL HA, MELTZER EO, KEMP JP, OSBORNE NK, WELCH MJ. Comparison of intranasal cromolyn sodium 4%, an oral terfenadine for allergic rhinitis: symptoms, nasal cytology, nasal ciliary clearance and rhinomanometry. Ann Allergy 1991;66:237-244.
124. 124. LINDSAY-MILLER AC, CHAMBERS A. Group comparative trial of cromolyn sodium and terfenadine in the treatment of seasonal allergic rhinitis. Ann Allergy 1987;58:28-32.
125. 125. GONZALES JP, BROGDEN RN. Nedocromil sodium: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutical efficacy in the treatment of reversible obstructive airways disease. Drugs 1987;34:560-577.
126. 126. BELLIONI P, SAVINELLI F, PATALANO F, RUGGIERI F. A double blind group comparative study of nedocromil sodium in the treatment of seasonal allergic rhinitis. Rhinology 1988;26:281-287.
127. 127. DRUCE HM, GOLDSTEIN S, HELAMED J, GROSSMANN J, MOSS BA, TOWNLEY RG. A multicenter placebo controlled study of nedocromil sodium 1% nasal solution in ragweed seasonal allergic rhinitis. Ann Allergy 1990;65:212-216.
128. 128. BUKSTEIN DA, BIONDI RM, BLUMENTHAL MM, et al. Tilarin in combination with astemizole. Allergy 1996;51 Suppl 28:20-27.
129. 129. LEINO M, CARLSON C, JAANIO E, et al. Double-blind group comparative study of 2% nedocromil sodium eye drops with placebo eye drops in the treatment of seasonal allergic conjunctivitis. Ann Allergy 1990;64:398-402.
130. 130. MALM L, ÄNGGÅRD A. Vasoconstrictors. In: MYGIND N, NACLERIO RM, editors. Allergic and non-allergic rhinitis. Copenhagen: Munksgaard, 1993:95-100.
131. 131. HAMELS K, CLEMENT PAR. Decongestant capacity of two frequently used topical nasal decongestants in healthy persons. Acta Otolaryngol Belg 1994;48:265-269.
132. 132. BENDE M, LŌTH S. Vascular effects of topical oxymethazoline on human nasal mucosa. J Laryngol Otol 1986;100:285-288.
133. 133. ECCLES R, WILSON H. The parasympathetic secretory nerves of the nose of the cat. J Physiol 1973;230:213-223.
134. 134. WOOD CC, FIREMAN P, GROSSMAN J, WECKER M, MACGREGOR T. Product characteristics and pharmacokinetics of intranasal ipratropium bromide. J Allergy Clin Immunol 1995;95:1111-1116.
135. 135. KIRKEGAARD J, MYGIND N, MOLGAARD F, et al. Ordinary and high dose ipratropium in perennial nonallergic rhinitis. J Allergy Clin Immunol 1987;79:585-590.
136. 136. MYGIND N, BORUM P. Anticholinergic treatment of watery rhinorrhea. Am J Rhinol 1990;4:1-5.
137. 137. BENDE M, RUNDCRANTZ H. Treatment of perennial secretory rhinitis. ORL J Otorhinolaryngol Relat Spec 1985;47:303-306.
138. 138. BORUM P, MYGIND N, SCHULTZ LARSEN F. Intranasal ipratropium: a new treatment for perennial rhinitis. Clin Otolaryngol 1979;4:407-411.
139. 139. DOLOVICH J, KENNEDY L, VICKERSON F, KAZIM K. Control of the hypersecretion of vasomotor rhinitis by topical ipratropium bromide. J Allergy Clin Immunol 1987;80:274-278.
140. 140. KNIGHT A, KAZIM F, SALVATORY VA. A trial of intranasal Atrovent versus placebo in the treatment of vasomotor rhinitis. Ann Allergy 1986;57:348-354.
141. 141. BORUM P, OLSEN L, WINTHER B, MYGIND N. Ipratropium nasal spray: a new treatment of rhinorrhoea in the common cold. Am Rev Respir Dis 1981;123:418-420.
142. 142. MALMBERG H, GRAHNE B, HOLOPAINEN E, BINDER E. Ipratropium (Atrovent) in the treatment of vasomotor rhinitis of elderly patients. Clin Otolaryngol 1983;8:273-276.
143. 143. WAGENMANN M, BARROODY FM, JANKOWSKY R, et al. Onset and duration of inhibition of ipratropium bromide nasal spray on methacholine-induced nasal secretions. Clin Exp Allergy 1994;24:288-290.
144. 144. MELTZER EO, BRONSKY EA, FINDLAY SR. Dose-response study of ipratropium bromide nasal spray in perennial allergic rhinitis. J Allergy Clin Immunol 1991;87:150.
145. 145. GEORGITIS JW. The anticholinergic treatment of allergic perennial rhinitis. J Allergy Clin Immunol 1992;90:1071-1076.
146. 146. KAISER HB, FINDLAY SR, GEORGITIS JW, et al. Long-term treatment of perennial allergic rhinitis with ipratropium bromide nasal spray 0.06%. J Allergy Clin Immunol 1995;95:1128-1132.
147. 147. BORUM P, MYGIND N, SCHULTZ LARSEN F. Ipratropium treatment for rhinorrhoea in patients with perennial rhinitis. An open follow-up study of efficacy and safety. Clin Otolaryngol 1983;8:267-272.
148. 148. MILFORD CA, MUGLISTON TA, LUND VJ;, et al. Long-term safety and efficacy of intranasal ipratropium bromide. J Laryngol Otol 1990;104:123-125.
149. 149. GROTH S, DIRKSEN H, MYGIND N. The absence of systemic side-effects from high doses of ipratropium in the nose. Eur J Respir Dis 1983;64 Suppl 128:490-493.
150. 150. BOUSQUET J, LOCKEY R, MALLING H-J. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998;102:558-562.
151. 151. MALLING H-J. The position of immunotherapy in the European Academy of Allergology and Clinical Immunology. J Investig Allergol Clin Immunol 1997;7:356-357.
152. 152. MALLING H-J. Immunotherapy as an effective tool in allergy treatment. Allergy 1998;53:461-472.
153. 153. HORST M, HEJJAOUI A, HORST V, MICHEL FB, BOUSQUET J. Double blind, placebo-controlled rush immunotherapy with standardized Alternaria extract. J Allergy Clin Immunol 1990;85:460-472.
154. 154. VARNEY VA, GAGA M, FREW AJ, ABER VR, KAY AB, DURHAM SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991;302:265-269.
155. 155. DES ROCHES A, PARADIS L, KNANI J, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy 1996;51:430-434.
156. 156. DES ROCHES A, PARADIS L, MENARDO JL, BOUGES S, DAURES JP, BOUSQUET J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitization in children. J Allergy Clin Immunol 1997;99:450-453.
157. 157. Committee on Safety of Medicines. CSM update. Desensitizing vaccines. BMJ 1986;253:948.
158. 158. TABAR AI, GARCIA BE, RODRIGUEZ A, OLAGUIBEL JM, MURO MD, QUIRCE S. A prospective safety-monitoring study of immunotherapy with biologically standardized extracts. Allergy 1993;48:450-453.
159. 159. HEJJAOUI A, FERRANDO R, DHIVERT H, MICHEL FB, BOUSQUET J. Systemic reactions occurring during immunotherapy with standardized pollen extracts. J Allergy Clin Immunol 1992;89:925-933.
160. 160. DREBORG S, EINARSSON R. The major allergen content of allergenic preparations reflect their biological activity. Allergy 1992;47:418-423.
161. 161. International consensus report on the diagnosis and management of asthma. International Asthma Management Project. Allergy 1992;47:1-61.
162. 162. NORMAN PS. Is there a role for immunotherapy in the treatment of asthma? Yes. Am J Respir Crit Care Med 1996;154:1225-1226.
163. 163. BARNES P. Is there a role for immunotherapy in the treatment of asthma? No. Am J Respir Crit Care Med 1996;154:1227-1228.
164. 164. The current status of allergen immunotherapy. Report of a WHO/ IUIS working group. Allergy 1989;44:369-379.
165. 165. DUNBAR WP. The present state of knowledge of hayfever. J Hyg 1913;13:105.
166. 166. HOLT PG, BRITTEN D, SEDGWICK JD. Suppression of IgE responses by antigen inhalation: studies on the role of genetic and environmental factors. Immunology 1987;60:97-102.
167. 167. HOLT PG, BATTY JE, TURNER KJ. Inhibition of specific IgE responses in mice by pre-exposure to inhaled antigen. Immunology 1981;42:409-417.
168. 168. MILLER A, LIDER O, ROBERTS AB, SPORNS MB, WEINER HL. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen specific triggering. Proc Natl Acad Sci U S A 1992;89:421-425.
169. 169. BAGNASCO M, MARIANI G, PASSALACQUA G, et al. Absorption and distribution kinetics of the major Parietaria judaica allergen administered by noninjectable routes in healthy human beings. J Allergy Clin Immunol 1997;100:122-9.
170. 170. LOCKEY RF, BENEDICT LM, TURKELTAUB PC, BUKANTZ SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 1987;79:660-677.
171. 171. PASSALACQUA G, CANONICA GW. Alternative routes for specific allergen immunotherapy. J Investig Allergol Clin Immunol 1996;6:81-87.
172. 172. PASSALACQUA G, ALBANO M, PRONZATO C, et al. Long-term follow up of nasal immunotherapy to Parietaria: clinical and local immunological effects. Clin Exp Allergy 1997;27:904-908.
173. 173. PASSALACQUA G, ALBANO M, FREGONESE L, PRONZATO C, MELA GS, CANONICA GW. Randomized controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998;351:629-632.
174. 174. MALLING H-J, ABREU-NOGUEIRA J, ALVAREZ-CUESTA E, et al. Local immunotherapy. Allergy 1998;53:933-944.
175. 175. QUIRINO T, IEMOLI E, SICILIANI S, PARMIANI S, MILAZZO F. Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. Clin Exp Allergy 1996;26:1253-1261.
176. 176. WARNER JO. Early treatment of the atopic child. Pediatr Allergy Immunol 1997;8 Suppl 10:46-48.
177. 177. IIKURA Y, NASPITZ CK, MIKAWA H, et al. Prevention of asthma by ketotifen in infants with atopic dermatitis. Ann Allergy 1992;68:233-236.
178. 178. BUSTOS GJ, BUSTOS D, BUSTOS GJ, ROMERO O. Prevention of asthma with ketotifen in preasthmatic children: a three-year follow-up study. Clin Exp Allergy 1995;25:568-573.
179. 179. VERMEULEN J, MERCER M. Comparison of the efficacy and tolerability of topical levocabastine and sodium cromoglycate in the treatment of seasonal allergic rhinoconjunctivitis in children. Pediatr Allergy Immunol 1994;5:209-213.
180. 180. KNOTTNERUS IG, RILEY PA. A clinical overview of Tilarin. Allergy 1996;51 Suppl 28:28-34.
181. 181. SCHENKEL EJ, ELLIS MH, GROSS G, et al. Triamcinolone acetonide aqueous nasal spray does not alter adrenocortical function in children with allergic rhinitis. J Allergy Clin Immunol 1995;97:198.
182. 182. BRANNAN MD, HERRON JM, AFFRIME MB. Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin Ther 1997;19:1330-1339.
183. 183. FINDLAY CA, MACDONALD JF, WALLACE AM, et al. Childhood Cushing's syndrome induced by betamethasone nose drops and repeat prescriptions. BMJ 1998;317:739-740.
184. 184. HEDNER P, PERSSON M. Suppression of the hypothalamic pituitary adrenal axis after a single intramuscular injection of methylprednisolone acetate. Ann Allergy 1981;47:176-179.
185. 185. BLOM HM, SEVERIJNEN LA, VAN RIJSWIJK JB, MULDER PG, VAN WIJK RG, FOKKENS WJ. The long-term effects of capsaicin aqueous spray on the nasal mucosa. Clin Exp Allergy 1998;28:1351-1358.